Pacira BioSciences Dividends and Buybacks
Dividend criteria checks 0/6
Pacira BioSciences does not have a record of paying a dividend.
Key information
n/a
Dividend yield
2.9%
Buyback Yield
| Total Shareholder Yield | 2.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.
Dividend Yield vs Market
| Pacira BioSciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PCRX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast (PCRX) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PCRX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PCRX has not reported any payouts.